Mufg Securities Americas Inc. Purchases 11,619 Shares of Johnson & Johnson $JNJ

Mufg Securities Americas Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 21.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 64,944 shares of the company’s stock after purchasing an additional 11,619 shares during the quarter. Johnson & Johnson accounts for approximately 0.8% of Mufg Securities Americas Inc.’s investment portfolio, making the stock its 19th largest position. Mufg Securities Americas Inc.’s holdings in Johnson & Johnson were worth $12,042,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of JNJ. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $26,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson in the second quarter worth about $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. Finally, Compass Financial Services Inc lifted its stake in shares of Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after purchasing an additional 198 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Citigroup increased their price target on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. Argus upped their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. Finally, Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $232.70.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $245.53 on Tuesday. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $246.96. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a fifty day simple moving average of $221.69 and a two-hundred day simple moving average of $199.96. The stock has a market capitalization of $591.70 billion, a price-to-earnings ratio of 22.22, a P/E/G ratio of 2.35 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Company momentum from product mix and recent earnings beat — analysts and commentators point to rising oncology revenues, a MedTech recovery and an earnings surprise as drivers of upside for JNJ. Read More.
• Positive Sentiment: Potential major asset sale — reports say Johnson & Johnson is exploring a sale of its orthopedics unit DePuy Synthes as part of a planned separation; a successful divestiture could unlock cash/value and simplify the company. Read More.
• Positive Sentiment: Clinical data supports Pharma franchise — J&J presented three‑year TREMFYA ulcerative colitis data showing sustained outcomes, which supports longer‑term revenue prospects for immunology assets. Read More.
• Positive Sentiment: Dividend and income appeal remain intact — JNJ’s regular dividend (recently announced/ex‑dividend timing noted in filings) keeps the stock attractive to income and long‑term investors. Read More.
• Neutral Sentiment: Market reports highlight structural tailwinds in vision and cataract devices — sector growth forecasts (phaco systems, femtosecond lasers) could benefit J&J’s device franchises over time but are longer‑term drivers. Read More.
• Neutral Sentiment: Strategic partnerships and analyst noise — a first co‑funding agreement with Blackstone and mixed analyst notes/option activity are being watched but have produced muted immediate market reaction. Read More.
• Negative Sentiment: Bayer lawsuit raises litigation overhang — Bayer sued J&J and Janssen in New York over claims around its Nubeqa prostate‑cancer drug, creating potential legal costs, distraction and uncertainty for Janssen’s oncology positioning. Read More.
• Negative Sentiment: Insider selling disclosed — EVP Timothy Schmid filed a sale of 1,322 shares (additional prior sales also disclosed); routine but may be viewed by some investors as profit‑taking. Read More.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.